Coreline Soft and Optellum announce intent to collaborate to advance AI across the lung cancer pathway
Proposed collaboration would make Coreline Soft's FDA-cleared lung nodule detection capability available through Optellum's LungOS® platform OXFORD, England and SEOUL, South Korea, Aug. 13, 2026 /PRNewswire/ -- Optellum and Coreline Soft today...
Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone...
Optellum Secures TGA Approval to Expand AI-Enabled Lung Nodule Solution To Australia
OXFORD, England, Feb. 27, 2026 /PRNewswire/ -- Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration (TGA) class IIb approval in Australia for the...